Shed Review: Honest Look at Pricing, GLP-1 Plans, and Pros/Cons

Shed provides compounded semaglutide and compounded tirzepatide through a standard telehealth model. You complete an online intake covering your health history, BMI, current medications, and weight loss goals. A licensed provider reviews your submission and issues a prescription if you qualify. The medication ships from a licensed compounding pharmacy directly to your door.

The standard semaglutide titration protocol at Shed starts at 0.25mg weekly, stepping up every 4 weeks based on your tolerance and response. The goal is to reach the dose where appetite suppression is meaningful without GI side effects being severe enough to interfere with daily life. Most patients spend 12-16 weeks reaching their maintenance dose of 1.0-2.4mg weekly.

Monthly provider check-ins are included in the subscription. These appointments confirm you are tolerating the current dose, assess your weight loss progress, and make dosing decisions for the next month. Between check-ins, messaging support is available through the platform for side effect questions or concerns.

What Shed does not build into the program: structured nutrition coaching, one-on-one dietitian sessions, exercise programming, or a behavioral health component. The platform covers the medical side of GLP-1 treatment. The lifestyle work is on you.

Shed offers both GLP-1 options, and the clinical difference is meaningful. Semaglutide activates the GLP-1 receptor to suppress appetite, slow gastric emptying, and reduce caloric intake - in the STEP 1 trial participants lost an average of 14.9% of body weight over 68 weeks at the 2.4mg maintenance dose (individual results vary).

Compounded semaglutide - prepared by a licensed compounding pharmacy and not FDA-approved, though not FDA-approved - is Shed's primary offering. Clinical trial data from the STEP program showed average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg maintenance dose. For a 230-pound person, that's roughly 34 pounds. The medication works by activating GLP-1 receptors, reducing appetite, slowing gastric emptying, and improving insulin sensitivity.

Compounded tirzepatide - containing tirzepatide, the active ingredient in Zepbound and Mounjaro, though not FDA-approved - activates both GLP-1 and GIP receptors. The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose over 72 weeks, making tirzepatide the more potent option for patients who tolerate it. Shed's tirzepatide is priced higher than semaglutide, consistent with the broader market.

For patients starting GLP-1 treatment for the first time without prior experience with either medication, Shed providers typically recommend beginning with semaglutide. The longer real-world track record, well-understood side effect profile, and lower cost make it the natural starting point. Tirzepatide is often recommended for patients who have tried semaglutide with insufficient weight loss response or for those who specifically request it.

Shed prices compounded semaglutide by plan length rather than by dose. Its semaglutide product page, price-verified September 17, 2026, lists $199 per month on a 1-month plan, $179 per month on a 6-month plan and $159 per month on a 12-month plan, so the $159 headline on the homepage is the 12-month rate. What Shed does not publish is a dose-by-dose ladder, so whether a higher maintenance dose costs more than the plan price is not something you can look up before you sign up. Compounded tirzepatide has its own product page with the same structure: $299 per month on a 1-month plan, $269 on 6 months and $239 on 12 months, price-verified September 17, 2026.

What sits behind checkout is the rest: what happens if you cancel partway through a 6-month or 12-month plan, whether the plan price holds when your dose changes, and what the subscription renews at. None of that is stated on the product page. So treat the plan price as the first question rather than the answer: ask what is bundled in, what you owe if you stop, and whether the quote covers the dose you expect to be on.

Shed operates on a cash-pay model - no insurance billing, no prior authorization navigation, no insurance paperwork. This is standard for compounded GLP-1 platforms because compounded medications are not covered by insurance formularies. If you have insurance coverage for branded Wegovy or Zepbound through your employer plan, a platform that helps with prior authorization (like PlushCare or Ro) might save you money. For everyone else, Shed's cash-pay pricing is competitive.

If you carry an HSA or FSA card, confirm at checkout whether Shed accepts it, and work any tax benefit out against the total you are actually quoted rather than against the starting figure.

Shed sources compounded semaglutide and tirzepatide from FDA-registered 503B outsourcing facilities. This regulatory designation matters for compounded injectable medications. 503B facilities are subject to FDA inspection, must follow current Good Manufacturing Practice standards, and conduct batch testing for sterility, potency, and contamination. The distinction between 503B and unregulated compounders is the difference between medication that meets pharmaceutical-grade production standards and medication that does not.

The medication is shipped as pre-filled injection pens or vials depending on dose and availability. Injection training materials are included with the first shipment, and the provider check-in system allows for injection technique questions if you are new to self-administered subcutaneous injections.

Proper storage matters for compounded semaglutide: refrigerate at 36-46°F upon arrival and do not freeze. Shed ships with appropriate cold-chain packaging. Plan to be available to receive the first shipment or have it held at a secure location.

The FDA has issued guidance on the regulatory status of compounded GLP-1 medications that has evolved as the branded shortage designation has changed. Patients using compounded GLP-1 medications should be aware that the regulatory landscape for compounding is subject to change, which could affect availability.

GLP-1 medications have predictable, well-documented gastrointestinal side effects: nausea affects approximately 40% of patients during dose escalation, with constipation, diarrhea, and vomiting also common in the first 4-8 weeks. These effects diminish as the body adjusts to each dose level.

Shed works best for a specific patient profile: adults who meet GLP-1 eligibility criteria (BMI 30+ or BMI 27+ with a weight-related comorbidity), are comfortable with the self-injection process, do not require structured behavioral support to make dietary changes, and want medication-forward access at a competitive price.

The platform is a natural fit for patients who have done their homework on GLP-1 medications and want to get started efficiently rather than navigating a complex intake process or paying for program features they do not intend to use. If you already understand how semaglutide works, what the titration schedule looks like, and what dietary adjustments support the medication, Shed delivers the prescription access without the overhead.

Shed is less suited for patients who need significant behavioral support alongside the medication - those who want weekly dietitian check-ins, structured meal planning, or fitness coaching integrated into their program. For that level of support, platforms like Ro Body or dedicated medical weight loss programs provide more infrastructure at a higher price point.

Patients with complex metabolic conditions - type 2 diabetes requiring careful HbA1c monitoring, kidney disease affecting medication metabolism, or cardiovascular history needing close clinical oversight - benefit from a platform with more capable lab monitoring integration than Shed currently offers.

The clinical evidence on long-term GLP-1 treatment consistently shows substantial weight regain when the medication is stopped. The STEP 4 extension trial found that trial participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This makes GLP-1 treatment effectively a long-term commitment rather than a short-term course.

Shed providers raise this during check-ins as you approach your goal weight. The options are: continue at a maintenance dose indefinitely, attempt gradual dose reduction with careful monitoring, or transition to behavioral strategies that may support weight maintenance without medication. The evidence for the third option is limited - the biological drivers of weight regain (increased appetite, reduced energy expenditure, altered gut hormones) are suppressed by the medication and reassert themselves when it is removed.

If you plan to stay on treatment for years rather than months, the cost is a standing commitment worth pinning down before you start. The figures Shed puts in public are plan prices, $159 to $199 per month for semaglutide depending on whether you commit to 12 months or 1, and none of them says what a higher maintenance dose costs. Ask what your maintenance dose costs and what the subscription renews at, then build your own long-run number from the quote you are given.

There may be room to move on that. Shed providers can adjust dosing based on clinical response, and if you hold your results at a dose below your maximum titration level, ask whether your monthly charge follows the dose down. The answer decides what the long run actually costs you.

In the competitive compounded GLP-1 market, Shed positions alongside iVIM Health and Skinny.Rx as a lower-cost, medication-focused option. The differentiators come down to pricing, support depth, and platform experience.

Against Ro Body - which offers more capable clinical support, lab integration, and dietary coaching - Shed is less expensive but provides less structured support. If you value monthly nutrition counseling or integrated lab monitoring, the price premium at those platforms is justified by the services you receive.

Against hims, a price comparison needs more than two headline figures. Shed publishes plan prices by commitment length and nothing about what a maintenance dose costs, so the only fair way to line the two up is to get a quote from each for the dose you expect to be on. Weigh what each one includes at the same time, because how often a provider actually reviews you is part of what you are buying.

The clearest advantage Shed has over most competitors is simplicity. The intake is straightforward, the clinical model is clean, and the published prices are three plan lengths per medication rather than a menu of tiers to decode. There are no upsells, no add-on packages, no app features requiring engagement to access the subscription value. If you want uncomplicated access to a medication you have already decided to try, that simplicity is a genuine feature.